ClinicalTrials.gg
CompletedNCT00515450Updated Jul 30, 2010

Efficacy and Safety Study of GB-0998 for Treatment of Generalized Myasthenia Gravis

A Phase 3 interventional study of GB-0998 (Intravenous immunoglobulin) and Plasmapheresis in Generalized Myasthenia Gravis, sponsored by Benesis Corporation. Completed at 1 site in Japan. Open to participants aged 16 Years and older. Per ClinicalTrials.gov, last updated 2010-07-30.

Sponsored by Benesis Corporation · Phase 3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
46
Allocation
Randomized
Ages
16 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 42 studies in Myasthenia Gravis with a site in Japan — 10 open to participants now, 20 under way, 15 of them phase 3. Myasthenia Gravis · Japan.

Planned enrollment
31st of 41
46 · median 125
Started
2007
the only one that year
Phase 3
35 of 42
5 open now
Registered
4th of 42
by date
Lead sponsor
1 of 42
Benesis Corporation

Among the 42 studies in Myasthenia Gravis with a site in Japan, this one is the 31st largest by planned enrollment of the 41 interventional ones that give a count, is the only one that started in 2007, is one of 35 in phase 3, and was the 4th registered.

Myasthenia Gravis

331 studies on the registry are indexed under Myasthenia Gravis; 145 are open to participants now.

Browse Myasthenia Gravis studies →

Open to participants now

10 of the 42 studies in Myasthenia Gravis with a site in Japan are open now. Recruiting first, the newest first:

5 more — sign in →

All 10 open studies →

A study can be open while its sites in Japan have not opened yet or have stopped. Only those recruiting at a site in Japan →

Who these studies take

Of the 104 Myasthenia Gravis studies recruiting now, 64 (62%) set no upper age limit and 23 (22%) stop at 75 or younger; 16 take children under 18; 13 take healthy volunteers.

This study: 16 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 42 studies in Myasthenia Gravis with a site in Japan, or all of them as a file.
02

Study summary

This randomized controlled, multi-center study will carry out to assess the efficacy of GB-0998 compared to plasmapheresis in the treatment of the generalized Myasthenia Gravis based on the changes in Quantitative Myasthenia Gravis score (QMG score) as primary endpoint, and in addition, to assess the safety of GB-0998

03

Conditions studied

  • Generalized Myasthenia Gravis

Browse trials for

Keywords

  • Myasthenia Gravis
04

Who can participate

Ages eligible
16 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients diagnosed as generalized myasthenia gravis
  • Patients who are not controlled by current therapy and need plasmapheresis therapy
  • Patients who have the high-dose therapy for over a month in past years, and also who take steroid or on the day of consent
  • Patients who had not any dose increase or new dosing of steroid or immunosuppressant within 4 weeks prior to enrollment

Exclusion criteria

Exclusion Criteria:

  • Patients who received pulse therapy, globulin therapy or plasmapheresis therapy within 12 weeks prior to enrollment
  • Patients who had undergone thymectomy within 24 weeks prior to enrollment
  • Patients with 3 points item in bulbar symptom of MG-ADL scale
  • Patients with severe hepatic disorder, severe renal disorder or severe heat disorder
  • Patients who have received treatment of malignant tumors
  • Patients who have the anamnesis of shock or to this drug
  • Patients who have been diagnosed as hereditary fructose intolerance
  • Patients who have the anamnesis of cerebral infarction or symptom of these diseases
  • Patients who have been diagnosed as IgA deficiency in their past history
  • Pregnant, lactating, and probably pregnant patients, and patients who want to become pregnant
  • Patients who were administered other drug within 12 weeks before consent
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Investigator)
Enrollment
46 participants (estimated)

Study arms

  • Experimental
    1

    Biological: GB-0998 (Intravenous immunoglobulin)

  • Active comparator
    2

    Procedure: Plasmapheresis

Interventions

06

What researchers measure

Primary outcomes

  1. Changes in QMG score

    Time frame: at 4 weeks

Secondary outcomes

  1. Changes of QMG score, MG-ADL scale, anti-acetylcholine receptor antibody levels

    Time frame: from beginning of the treatment through 4th week

07

Study locations

1 site
  • Nagasaki University
    Nagasaki, 852-8501, Japan
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2007, a primary completion of May 2010 and a completion of Jun 2010. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 10, 2007
First posted
Aug 13, 2007
Start
Jul 2007
Primary completionActual
May 2010
CompletionActual
Jun 2010
Last update
Jul 30, 2010
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 30, 2010, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00515450
Lead sponsor
Benesis Corporation
First posted
Aug 13, 2007
Start date
Jul 2007
Primary completion
May 2010
Completion
Jun 2010
Last update
Jul 30, 2010

Study contacts

Masaharu Takamori, Director
study chair · Neurological Center Kanazawa-Nishi Hospital

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2010. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Immunoglobulins, Intravenous

Start the discussion